Cargando…

Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives

Surgical resection followed by adjuvant cisplatin-based chemotherapy is the recommended treatment for patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC). Even with the best management, recurrence is common and increases with disease stage (stage I: 26–45%; stage II: 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Kris, Mark G., Mitsudomi, Tetsuya, Peters, Solange
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183392/
https://www.ncbi.nlm.nih.gov/pubmed/37197636
http://dx.doi.org/10.21037/tlcr-22-723
_version_ 1785041938572902400
author Kris, Mark G.
Mitsudomi, Tetsuya
Peters, Solange
author_facet Kris, Mark G.
Mitsudomi, Tetsuya
Peters, Solange
author_sort Kris, Mark G.
collection PubMed
description Surgical resection followed by adjuvant cisplatin-based chemotherapy is the recommended treatment for patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC). Even with the best management, recurrence is common and increases with disease stage (stage I: 26–45%; stage II: 42–62%; stage III: 70–77%). For patients with metastatic lung cancer and tumours that harbour epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKIs) have improved survival. Their effectiveness in advanced stages of NSCLC raises the possibility that these agents may improve outcomes for patients with resectable EGFR-mutated lung cancer. In the ADAURA study, adjuvant osimertinib provided a significant improvement in disease-free survival (DFS) and reduced central nervous system (CNS) disease recurrence in patients with resected stage IB–IIIA EGFR-mutated NSCLC, with or without prior adjuvant chemotherapy. To reap the maximum benefits of EGFR-TKIs for patients with lung cancer, the early and rapid identification of EGFR mutations [and other oncogenic drivers, such as programmed cell death-ligand 1 (PD-L1), with matched targeted therapies] in diagnostic pathologic specimens has become essential. To ensure patients receive the most appropriate treatment, routine, comprehensive histological, immunohistochemical, and molecular analyses (with multiplex next generation sequencing) should be undertaken at the time of diagnosis. The potential for personalised treatments to cure more patients with early-stage lung cancer can only be realised if all therapies are considered when the care plan is formulated, by the multi-specialty experts managing patients. In this review, we discuss the progress and prospects for adjuvant treatments as part of a comprehensive plan of care for patients with resected stages I–III EGFR-mutated lung cancer, and explore how the field could go beyond DFS and overall survival to make cure a more frequent outcome of treatment in patients with resected EGFR-mutated lung cancer.
format Online
Article
Text
id pubmed-10183392
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-101833922023-05-16 Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives Kris, Mark G. Mitsudomi, Tetsuya Peters, Solange Transl Lung Cancer Res Review Article Surgical resection followed by adjuvant cisplatin-based chemotherapy is the recommended treatment for patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC). Even with the best management, recurrence is common and increases with disease stage (stage I: 26–45%; stage II: 42–62%; stage III: 70–77%). For patients with metastatic lung cancer and tumours that harbour epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKIs) have improved survival. Their effectiveness in advanced stages of NSCLC raises the possibility that these agents may improve outcomes for patients with resectable EGFR-mutated lung cancer. In the ADAURA study, adjuvant osimertinib provided a significant improvement in disease-free survival (DFS) and reduced central nervous system (CNS) disease recurrence in patients with resected stage IB–IIIA EGFR-mutated NSCLC, with or without prior adjuvant chemotherapy. To reap the maximum benefits of EGFR-TKIs for patients with lung cancer, the early and rapid identification of EGFR mutations [and other oncogenic drivers, such as programmed cell death-ligand 1 (PD-L1), with matched targeted therapies] in diagnostic pathologic specimens has become essential. To ensure patients receive the most appropriate treatment, routine, comprehensive histological, immunohistochemical, and molecular analyses (with multiplex next generation sequencing) should be undertaken at the time of diagnosis. The potential for personalised treatments to cure more patients with early-stage lung cancer can only be realised if all therapies are considered when the care plan is formulated, by the multi-specialty experts managing patients. In this review, we discuss the progress and prospects for adjuvant treatments as part of a comprehensive plan of care for patients with resected stages I–III EGFR-mutated lung cancer, and explore how the field could go beyond DFS and overall survival to make cure a more frequent outcome of treatment in patients with resected EGFR-mutated lung cancer. AME Publishing Company 2023-04-07 2023-04-28 /pmc/articles/PMC10183392/ /pubmed/37197636 http://dx.doi.org/10.21037/tlcr-22-723 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Kris, Mark G.
Mitsudomi, Tetsuya
Peters, Solange
Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
title Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
title_full Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
title_fullStr Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
title_full_unstemmed Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
title_short Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives
title_sort adjuvant therapies in stages i–iii epidermal growth factor receptor-mutated lung cancer: current and future perspectives
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183392/
https://www.ncbi.nlm.nih.gov/pubmed/37197636
http://dx.doi.org/10.21037/tlcr-22-723
work_keys_str_mv AT krismarkg adjuvanttherapiesinstagesiiiiepidermalgrowthfactorreceptormutatedlungcancercurrentandfutureperspectives
AT mitsudomitetsuya adjuvanttherapiesinstagesiiiiepidermalgrowthfactorreceptormutatedlungcancercurrentandfutureperspectives
AT peterssolange adjuvanttherapiesinstagesiiiiepidermalgrowthfactorreceptormutatedlungcancercurrentandfutureperspectives